On the other hand, both RXRA and PANK1 are involved in signaling pathways controlling the metabolism of lipids by hepatocytes [85,86], while downregulation may contribute to serious liver disorders, such as NAFLD. Here, RXRA is linked to metabolic dysfunction-associated steatotic liver disease.